Surrozen, Inc.

SRZN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Revenue $5.0M $5.0M $528.0K $983.0K $983.0K $983.0K $655.0K $10.0M
Cost of Revenue — — — — — — — —
Gross Profit — — — — — — — —
Gross Margin — — — — — — — —
Operating Expenses
Research & Development $8.5M $9.3M $9.0M $7.8M $6.0M $6.6M $5.4M $5.2M
SG&A Expense $6.9M $6.1M $4.2M $4.1M $4.0M $4.0M $3.9M $3.6M
Operating Income $-10.4M $-10.5M $-12.6M $-10.9M $-9.0M $-9.6M $-8.6M $1.2M
Operating Margin -207.4% -209.1% -2,393.8% -1,107.3% -917.3% -971.6% -1,311.8% 12.3%
Interest Expense — — — — — — — —
Pretax Income — — — — — — — —
Income Tax Expense $0 $0 — — $0 $0 — —
Net Income $50.2M $-127.5M $-183.2M $-71.6M $39.7M $-27.0M $-28.0M $-1.4M
Net Margin 1,003.5% -2,550.1% -34,689.2% -7,288.2% 4,043.3% -2,743.6% -4,280.8% -14.3%
EPS (Basic) $2.75 $-11.65 $-19.13 $-2.79 $0.85 $-2.48 $-3.00 $-0.15
EPS (Diluted) $-0.41 $-11.65 $-19.13 $-2.79 $0.85 $-2.48 $-3.00 $-0.15
Shares Outstanding (Basic) 11.7M 10.9K 9.8M 25.7K 25.6M 25.5M 9.8M 9.7M
Shares Outstanding (Diluted) 23.1M 10.9K 9.8M 25.7K 25.6M 25.5M 9.8M 9.7M
Dividends Per Share — — — — — — — —
← Newer Page 1 of 2 Older →